新疆医科大学学报
新疆醫科大學學報
신강의과대학학보
JOURNAL OF XINJIANG MEDICAL UNIVERSITY
2014年
5期
519-523
,共5页
王月栋%刘凯%黄莉%葛红%王若峥
王月棟%劉凱%黃莉%葛紅%王若崢
왕월동%류개%황리%갈홍%왕약쟁
核内表皮生长因子受体%血管内皮生长因子%微血管密度%早期非小细胞肺癌
覈內錶皮生長因子受體%血管內皮生長因子%微血管密度%早期非小細胞肺癌
핵내표피생장인자수체%혈관내피생장인자%미혈관밀도%조기비소세포폐암
nuclear epidermal growth factor receptor%vascular endothelial growth factor%microvessel den-sity%early stage non-small cell lung cancer
目的:探讨 VEGF、核内 EGFR及CD105在早期非小细胞肺癌的表达情况及其与早期非小细胞肺癌临床病理特征的关系。方法选择30例手术切除的早期非小细胞肺癌组织及癌旁正常组织,应用免疫组化方法检测 VEGF、核内 EGFR及CD105的表达情况,分析3者之间的相互关系及临床意义。计量资料采用t检验,计数资料用卡方检验或四格表确切概率检验,两者相关性采用非参数Spearman等级相关性分析。结果 VEGF在30例早期非小细胞肺癌组织和癌旁正常组织中的阳性表达率分别为53.5%和26.7%,差异具有统计学意义(P <0.05)。核内 EGFR在癌组织和癌旁正常组织中的阳性表达率分别为16.7%和0%,差异无统计学意义(P >0.05),CD105标记的微血管密度值(MVD)在癌组织与癌旁正常组织中分别为(17.3±5.6)和(8.9±4.2),差异具有统计学意义(P <0.05)。VEGF与核内 EGFR的表达与肿瘤复发转移有关,差异具有统计学意义(P <0.05), VEGF、核内 EGFR的表达及CD105标记的 MVD值与与患者年龄、性别、吸烟、肿块大小、病理类型、临床分期、分化程度、解剖学类型差异无统计学意义(P >0.05)。VEGF在癌组织中的表达与 MVD呈正相关性(r =0.516,P=0.004),VEGF的阳性表达与核内 EGFR 的阳性表达、核内 EGFR 的阳性表达与 MVD 之间无相关性(P >0.05)。结论 VEGF、核内 EGFR及CD105在早期 NSCLC均有表达,VEGF、核内 EGFR的表达与早期非小细胞肺癌的复发转移有关。
目的:探討 VEGF、覈內 EGFR及CD105在早期非小細胞肺癌的錶達情況及其與早期非小細胞肺癌臨床病理特徵的關繫。方法選擇30例手術切除的早期非小細胞肺癌組織及癌徬正常組織,應用免疫組化方法檢測 VEGF、覈內 EGFR及CD105的錶達情況,分析3者之間的相互關繫及臨床意義。計量資料採用t檢驗,計數資料用卡方檢驗或四格錶確切概率檢驗,兩者相關性採用非參數Spearman等級相關性分析。結果 VEGF在30例早期非小細胞肺癌組織和癌徬正常組織中的暘性錶達率分彆為53.5%和26.7%,差異具有統計學意義(P <0.05)。覈內 EGFR在癌組織和癌徬正常組織中的暘性錶達率分彆為16.7%和0%,差異無統計學意義(P >0.05),CD105標記的微血管密度值(MVD)在癌組織與癌徬正常組織中分彆為(17.3±5.6)和(8.9±4.2),差異具有統計學意義(P <0.05)。VEGF與覈內 EGFR的錶達與腫瘤複髮轉移有關,差異具有統計學意義(P <0.05), VEGF、覈內 EGFR的錶達及CD105標記的 MVD值與與患者年齡、性彆、吸煙、腫塊大小、病理類型、臨床分期、分化程度、解剖學類型差異無統計學意義(P >0.05)。VEGF在癌組織中的錶達與 MVD呈正相關性(r =0.516,P=0.004),VEGF的暘性錶達與覈內 EGFR 的暘性錶達、覈內 EGFR 的暘性錶達與 MVD 之間無相關性(P >0.05)。結論 VEGF、覈內 EGFR及CD105在早期 NSCLC均有錶達,VEGF、覈內 EGFR的錶達與早期非小細胞肺癌的複髮轉移有關。
목적:탐토 VEGF、핵내 EGFR급CD105재조기비소세포폐암적표체정황급기여조기비소세포폐암림상병리특정적관계。방법선택30례수술절제적조기비소세포폐암조직급암방정상조직,응용면역조화방법검측 VEGF、핵내 EGFR급CD105적표체정황,분석3자지간적상호관계급림상의의。계량자료채용t검험,계수자료용잡방검험혹사격표학절개솔검험,량자상관성채용비삼수Spearman등급상관성분석。결과 VEGF재30례조기비소세포폐암조직화암방정상조직중적양성표체솔분별위53.5%화26.7%,차이구유통계학의의(P <0.05)。핵내 EGFR재암조직화암방정상조직중적양성표체솔분별위16.7%화0%,차이무통계학의의(P >0.05),CD105표기적미혈관밀도치(MVD)재암조직여암방정상조직중분별위(17.3±5.6)화(8.9±4.2),차이구유통계학의의(P <0.05)。VEGF여핵내 EGFR적표체여종류복발전이유관,차이구유통계학의의(P <0.05), VEGF、핵내 EGFR적표체급CD105표기적 MVD치여여환자년령、성별、흡연、종괴대소、병리류형、림상분기、분화정도、해부학류형차이무통계학의의(P >0.05)。VEGF재암조직중적표체여 MVD정정상관성(r =0.516,P=0.004),VEGF적양성표체여핵내 EGFR 적양성표체、핵내 EGFR 적양성표체여 MVD 지간무상관성(P >0.05)。결론 VEGF、핵내 EGFR급CD105재조기 NSCLC균유표체,VEGF、핵내 EGFR적표체여조기비소세포폐암적복발전이유관。
Objective To detect the expressions of vascular endothelial growth factor (VEGF),nuclear epi-dermal growth factor receptor (EGFR)and CD105 in the early non-small cell lung cancer and analyze the relationship of these indices with the clinicopathologic features of early stage NSCLC.Methods The ex-pression status of VEGF,nuclear EGFR and CD105 were examined by immunohistochemistric method (IHC)in 30 cases of early-stage non-small cell lung cancer and adjacent normal tissue.Results The posi-tive rates of VEGF of 30 patients with early stage non-small cell lung cancer and adjacent normal tissue were 53.5% and 26.7% respectively,and the difference was statistically significant (P <0.05).The posi-tive rates of nuclear EGFR of 30 patients with early stage non-small cell lung cancer and adjacent normal tissue were 16.7% and 0% respectively,and the difference was not statistically significant (P <0.05). MVD marked by CD105 of 30 patients with early stage non-small cell lung cancer and adjacent normal tis-sue were (17.3±5.6)and (8.9±4.2)in the adjacent tissues and normal tissues,and the difference was sta-tistically significant (P <0.05).The expression of VEGF and nuclear EGFR were significantly correlated with tumor recurrence and metastasis (r=0.516,P =0.004);The expression of VEGF and nucleus EG-FR,as well as the expression of nucleus EGFR and MVD were not significantly correlated (P >0.05). Conclusion The expressions of VEGF,nuclear EGFR and CD105 played an important role in the develop-ment of early-stage non-small cell lung cancer,and the expressions of VEGF and nuclear EGFR were rele-vant to the recurrence of early-stage non-small cell lung cancer.